Additional file 1: of The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

Autor: Wu, Yi-Ying, Hung-Chang Wu, Wu, Jia-En, Kuo-Yen Huang, Shuenn-Chen Yang, Si-Xuan Chen, Chao-Jung Tsao, Keng-Fu Hsu, Yuh-Ling Chen, Tse-Ming Hong
Rok vydání: 2019
Předmět:
DOI: 10.6084/m9.figshare.8426003.v1
Popis: Figure S1. The dose determination for BEZ235 and cisplatin in the in vivo study. Figure S2. Viability of BEZ235-treated NSCLC cell lines expressing wild-type EGFR or activating mutants of EGFR. Figure S3. Regrowth of BEZ235-treated NSCLC cells after withdrawal of the drug. Figure S4. Effects of BEZ235 on apoptosis, autophagy and cell cycle. Figure S5. β-catenin is not involved in the BEZ235-induced decrease in cyclin D. Figure S6. BEZ235 synergistically enhances cisplatin-induced apoptosis in NSCLC cells. Figure S7. BEZ235 synergistically enhances BIBW2992-induced apoptosis in EGFR-TKIâ resistant NSCLC cells. (PDF 1190 kb)
Databáze: OpenAIRE